Abiomed Inc

Find Ratings Reports
ABMD : NASDAQ : Health Care
$117.99 up 3.00 | 2.60%
Today's Range: 115.24 - 119.93
Avg. Daily Volume: 615,600
07/29/16 - 3:59 PM ET

Financial Analysis


ABIOMED INC's gross profit margin for the first quarter of its fiscal year 2016 is essentially unchanged when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth. ABIOMED INC is extremely liquid. Currently, the Quick Ratio is 6.12 which clearly shows the ability to cover any short-term cash needs. ABMD managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.

During the same period, stockholders' equity ("net worth") has increased by 22.48% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY16 Q1 FY15
Net Sales ($mil)103.073.43
EBITDA ($mil)0.015.85
EBIT ($mil)21.2315.18
Net Income ($mil)12.918.86


Balance Sheet Q1 FY16 Q1 FY15
Cash & Equiv. ($mil)223.17154.92
Total Assets ($mil)429.31352.01
Total Debt ($mil)0.00.0
Equity ($mil)377.33308.05


Profitability Q1 FY16 Q1 FY15
Gross Profit Margin85.3786.1
EBITDA Margin0.021.57
Operating Margin20.6220.67
Sales Turnover0.840.72
Return on Assets9.8235.29
Return on Equity11.1840.33
Debt Q1 FY16 Q1 FY15
Current Ratio6.956.73
Debt/Capital0.00.0
Interest Expense0.00.0
Interest Coverage0.00.0


Share Data Q1 FY16 Q1 FY15
Shares outstanding (mil)43.0142.02
Div / share0.00.0
EPS0.290.2
Book value / share8.777.33
Institutional Own % n/a n/a
Avg Daily Volume623806.0723008.0

Valuation


BUY. ABIOMED INC's P/E ratio indicates a significant premium compared to an average of 44.86 for the Health Care Equipment & Supplies industry and a significant premium compared to the S&P 500 average of 25.11. For additional comparison, its price-to-book ratio of 13.11 indicates a significant premium versus the S&P 500 average of 2.81 and a significant premium versus the industry average of 4.95. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. Upon assessment of these and other key valuation criteria, ABIOMED INC proves to trade at a premium to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
ABMD 123.69 Peers 44.86   ABMD NA Peers 33.84

Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.

ABMD is trading at a significant premium to its peers.

 

Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.

Ratio not available.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
ABMD 66.88 Peers 29.75   ABMD 3.89 Peers 0.88

Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.

ABMD is trading at a significant premium to its peers.

 

Premium. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

ABMD trades at a significant premium to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
ABMD 13.11 Peers 4.95   ABMD -67.14 Peers 14.55

Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

ABMD is trading at a significant premium to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, ABMD is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
ABMD 13.78 Peers 4.69   ABMD 40.86 Peers 21.03

Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

ABMD is trading at a significant premium to its industry.

 

Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.

ABMD has a sales growth rate that significantly exceeds its peers.

 

 

Latest Stock Upgrades/Downgrades